[A clinical trial of radioimmunoguided surgery for gastric cancer].
A clinical trial of radioimmunoguided surgery (RIGS) using 131I labeled monoclonal antibody (McAb) 3H11 and a portable gamma-detector Oncoprobe II was performed on 25 cases with gastric cancer in this study. The 25 patients involved in the study included 4 for intravenous administration of 131I-3H11, 19 for injection of 131I-3H11 into submucosa by endoscope and 2 for receiving radiolabeled normal mouse IgG by endoscope as control. The sensitivity in detecting tumor infiltrated gastric wall was 94.6%, the specificity was 96.7% and the accuracy was 95.9%. For the detection of metastatic lymph nodes, the sensitivity of RIGS was 99.2%, the specificity was 97.7% and the accuracy was 98.8%. The results described above indicate that the RIGS system for gastric cancer is very promising for identification of the extent of tumor, metastatic lymph nodes and reasonable radical resection with higher curability and better life quality for patients.